Effect of Combined Chelation Therapy with Deferiprone and Deferoxamine on Left Ventricular Diastolic Function in Adult β-Thalassemia Major Patients

REFERENCES

• Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, refractory anemia with hemochromatosis. Circulation. 1964;30(5):698–705.
   PubMedGoogle Scholar
• Borgna-Pignatti C, Rigolotto S, De Stefano P, Survival and complications in patients with thalassemia major treated with transfusion and desferrioxamine. Haematologica. 2004;89(10): 1187–1193.
   PubMed Web of Science ®Google Scholar
• Schellhammer PF, Engle MA, Hagstrom WC. Histochemical studies of the myocardium and conduction system in acquired iron-storage disease. Circulation. 1967;35(4):631–637.
   PubMedGoogle Scholar
• Kyriakou K, Michailides Y, Senkus R, Ultrastructural pathology of the heart in patients with β-thalassemia major. Ultrastruct Pathol. 2000;24(2):75–81.
   PubMedGoogle Scholar
• Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med. 1971;51(2):209–221.
   PubMed Web of Science ®Google Scholar
• Jessup M, Manno CS. Diagnosis and management of iron- induced heart disease in Cooley's anemia. Ann NY Acad Sci. 1998;850:242–250.
   PubMedGoogle Scholar
• Kremastinos DT, Tiniakos G, Theodorakis GN, Katritsis DG, Toutouzas PK. Myocarditis in β-thalassemia major. A cause of heart failure. Circulation. 1995;91(1):66–71.
   PubMed Web of Science ®Google Scholar
• Kremastinos DT, Flevari P, Spyropoulou M, Vrettou H, Tsiapras D, Stavropoulos-Gioka CG. Association of heart failure in homozygous β-thalassemia with the major histocompatibility complex. Circulation. 1999;100(20):2074–2078.
   PubMed Web of Science ®Google Scholar
• Economou-Petersen E, Aessopos A, Kladi A, Apolipoprotein E ε-4 allele as a genetic risk factor for left ventricular failure in homozygous β-thalassemia. Blood. 1998;92(9):3455–3459.
   PubMed Web of Science ®Google Scholar
• Wu K-H, Chang J-G, Ho Y-J, Wu S-F, Peng C-T. Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patient's with β-thalassemia major. Hemoglobin 2006;30(2):251–256.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Michaelides Y, Kontos C, Kyriakou K, Kontogeorghes GJ. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin. 2008;32(1):17–28.
   PubMedGoogle Scholar
• Glickstein H, El RB, Link G, Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood. 2006;108(9):3195–3203.
   PubMed Web of Science ®Google Scholar
• Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH. Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med. 2006;84(5):349–364.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Nathan DG, MacMillan JH, Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med. 1994;331(9):574–578.
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Holden S, Davis B, Cardiovascular T2* magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171–2179.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Kontogeorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The protocol of the International Committee on Oral Chelators. Hemoglobin. 2006;30(2):239–249.
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Wonke B, Prescott E, Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet. 2002;360(9352):516–520.
   PubMedGoogle Scholar
• Tanner MA, Galanello R, Dessi C, A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876–1884.
   PubMed Web of Science ®Google Scholar
• Wu KH, Chang JS, Tsai CH, Peng CT. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with β-thalassemia major. Ann Hematol. 2004; 83(7):471–473.
   PubMed Web of Science ®Google Scholar
• Huanq YC, Chanq JS, Wu KH, Penq CT. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in β-thalassemia major patients. Hemoglobin. 2006; 30(2):229–238.
   PubMedGoogle Scholar
• Tsironi M, Deftereos S, Andriopoulos P, Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur J Haematol. 2005;74(1):84–85.
   PubMedGoogle Scholar
• Spirito P, Lupi G, Melevendi C, Vecchio C. Restrictive diastolic abnormalities identified by Doppler echocardiography in patients with thalassemia major. Circulation. 1990;82(1):88–94.
   PubMedGoogle Scholar
• Kremastinos DT, Tsiapras DP, Tsetsos GA, Rentoukas EI, Vretou HP. Toutouzas PK Left ventricular diastolic Doppler characteristics in β-thalassemia major. Circulation. 1993;88(3):1127–1135.
   PubMed Web of Science ®Google Scholar
• Kremastinos D, Tsiapras D, Kostopoulou A, Hamodraka E, Chaidaroglou AS, Kapsali ED. NT-proBNP levels and diastolic dysfunction in β-thalassaemia major patients. Eur J Heart Fail. 2007;9(5):531–536.
   PubMedGoogle Scholar
• Schiller NB, Shah PM, Crawford M, Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2(5):358–367.
   PubMedGoogle Scholar
• Ommen SR, Nishimura RA, Appleton CP, Clinical utility of Doppler echocardiography and Tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation. 2000;102(15):1788–1794.
   PubMed Web of Science ®Google Scholar
• Leonardi B, Margossian R, Colan SD, Powell AJ. Relationship of magnetic resonance imaging estimation of myocardial iron to left ventricular systolic and diastolic function in thalassemia. JACC Cardiovasc Imaging. 2008;1(5):579–581.
   PubMedGoogle Scholar
• Westwood MA, Wonke B, Maceira AM, Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major. J Magn Reson Imaging. 2005;22(2):229–233.
   PubMed Web of Science ®Google Scholar
• Bartfay WJ, Bartfay E. Iron-overload cardiomyopathy: evidence for a free radical--mediated mechanism of injury and dysfunction in a murine model. Biol Res Nurs. 2000;2(1):49–59.
   PubMedGoogle Scholar
• Glickstein H, Link G, Breuer W, Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood. 2006;108(9):3195–3203.
   PubMed Web of Science ®Google Scholar
• Peppe A, Positano V, Capra M, Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassemia major. Heart. 2009;95(20):1688–1693.
   PubMedGoogle Scholar
• Mc Murray JJ, Pfeffer MA. Heart failure. Lancet. 2005;365(9474):1877–1889.
   PubMedGoogle Scholar